Updated Study Data Suggests Efruxifermin Benefits Stage 2 or 3 MASH
source: shutterstock.com

Updated Study Data Suggests Efruxifermin Benefits Stage 2 or 3 MASH

Over the past few years, Akero Therapeutics has experienced high highs and low lows in its efforts to advance efruxifermin, an investigational drug for people living with metabolic dysfunction-associated steatohepatitis…

Continue Reading Updated Study Data Suggests Efruxifermin Benefits Stage 2 or 3 MASH
Highlights of ACMG 2024
source: shutterstock.com

Highlights of ACMG 2024

Perhaps 70- 85% of rare diseases have a root in genetics, - which is why continuous research and reporting is so critical for those with rare conditions. This is exactly…

Continue Reading Highlights of ACMG 2024